MabThera/MabThera SC Drug Interactions

At present, there are limited data on possible drug interactions with MabThera/Rituxan.
In CLL patients, co-administration with MabThera/Rituxan IV did not appear to have an effect on the pharmacokinetics of fludarabine or cyclophosphamide, in addition; there was no apparent effect of fludarabine and cyclophosphamide on the pharmacokinetics of MabThera/Rituxan.
Co-administration with methotrexate had no effect on the pharmacokinetics of MabThera/Rituxan IV in RA patients.
Patients with human anti-mouse antibody (HAMA) or human anti-chimeric anti-body (HACA) titers may develop allergic or hypersensitivity reactions when treated with other diagnostic or therapeutic monoclonal antibodies.
In the RA clinical trial program, 373 MabThera/Rituxan IV-treated patients received subsequent therapy with other disease-modifying antirheumatic drugs (DMARDs), of whom 240 received a biologic DMARD. In these patients the rate of serious infection while on MabThera/Rituxan IV (prior to receiving a biologic DMARD) was 6.1 per 100 patient years compared to 4.9 per 100 patient years following subsequent treatment with the biologic DMARD.